Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 16

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 16
---
 and academic experience in biopharmaceuticals, including as CEO of the Bill & Melinda Gates Medical Research Institute, SVP of Vaccine R&D at Wyeth/Pfizer, SVP of Research at Merck Research Laboratories, and member of the National Preparedness Advisory Committee, an advisory board to the Secretary of HHS • Has led the development of anti - infectious disease vaccines, including vaccines for human papillomavirus and rotavirus, and the first highly active antiretroviral therapies for HIV Ryan Spencer Chief Executive Officer • ~20 - years of escalating senior executive experience at Dynavax • Held senior leadership positions across every function of the Company • Project leader for the launch & commercialization of HEPLISAV - B Scott Myers Independent Chair • 30+ years of expertise in global pharmaceutical and medical technology industries as a CEO and Chairman • Successfully developed and commercialized many pharmaceutical products on multiple continents • Multiple public company exits through outright sales and asset sales Peter Paradiso • 30+ years of vaccine strategic planning and development expertise as an executive and researcher, as well as vaccine consultant • Former VP of New Business & Scientific Affairs for Pfizer Vaccines, and vast experience in pneumococcal conjugate vaccine development, including Prevnar 13 • Liaison member of the CDC’s Advisory Committee on Immunization Practices (ACIP) Elaine Sun • 30+ years of experience in investment banking and life sciences industries, including CFO of Halozyme Therapeutics and SutroVax ( Vaxcyte ) • Has played a key role in a broad range of transactions including mergers, acquisitions and financings valued in excess of $50B • ~40 years of experience with larger, complex organizations as well as significant experience with corporate transactions • F ormer VP of Pharmaceutical Development at Abbott Laboratories and Former VP of Clinical Research at SmithKline Beckman Pharmaceuticals • Has invested in multiple venture - backed life sciences companies, and served on multiple public company Boards Dynavax’s Board is Fit - for - Purpose… © Copyright DYNAVAX 2025 Up for Election Incumbent Director Francis Cano , Ph.D. • 30+ years of experience as a vaccine expert, with significant operational and financial experience • Developed HibTITER to prevent meningitis in infants through conjugate technology • Chief scientist to develop Prevnar to protect against otitis media in children and pneumonia in adults Appointed in Oct - 2021 Appointed in Feb - 2025 Appointed in Sep - 2020 Appointed in Feb -